Kane Biotech Inc.KNE.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · kanebiotech.com
Kane Biotech Inc. is a biotechnology company engaged in the research, development, and commercialization of technologies and products designed to prevent and remove microbial biofilms. The company's product portfolio includes wound care and surgical hydrogel products marketed under the revyve and coactiv+ brands, leveraging its proprietary DispersinB enzyme platform. Kane Biotech is headquartered in Winnipeg, Manitoba, Canada.
Key ratios
FCF / Sales
-6456.8%TTM
2025
-761.9%2024
-198.8%2023
-1403.6%
Net margin
-179.8%TTM
2024
293.1%
ROA
-54.5%TTM
2025
-62.4%2024
-56.9%2023
-37.1%
Revenue growth
-97.9%TTM
2025
-79.4%2024
1296.8%2023
-5.0%
Recent news
Kane Biotech to Host Commercial Update Webcast on September 16
Kane Biotech Expands Canadian Commercial Reach with Ontario Medical Supply Inc.
Kane Biotech Announces Second Quarter 2026 Financial Results
Kane Biotech's revyve Research Presented at Military Health System Research Symposium
Kane Biotech Announces Engagement of DNA Advisors
Kane Biotech Announces Results of Annual and Special Meeting of Shareholders
Kane Biotech Announces First Quarter 2026 Financial Results
Kane Biotech Restarts Commercial Activities and Strengthens North American Management
Track KNE.V in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer